GLP-1 Weight Loss Injections: How They Work and What to Expect

If you have been paying attention to conversations about weight loss over the past few years, you have probably heard the names: semaglutide, tirzepatide, Ozempic, Wegovy, Mounjaro, Zepbound. These medications — GLP-1 receptor agonists — have generated more genuine clinical excitement in the obesity medicine field than almost anything in decades. Patients are reporting meaningful weight loss. Research is confirming benefits well beyond the number on the scale. And for people who have tried everything and felt like they were fighting their own biology every step of the way, the experience of finally having a tool that works with the body’s own hormonal systems can feel transformative. But for all the attention these medications have received, there is still a lot of confusion about what they actually do, how they work, who is a good candidate, and what to realistically expect.

Part of the confusion comes from how differently these medications are discussed in different contexts — medical offices, social media, weight loss clinics, and news coverage all frame GLP-1 medications through very different lenses. Some coverage focuses on celebrities using them for vanity weight loss. Other coverage emphasizes risks without adequate context. Most coverage skips the actual science of how these drugs work at a hormonal level. Patients trying to make informed decisions about their health deserve something more accurate and complete than what they’re typically getting.

At SustainMD, Dr. Allison Barbee brings a trained obesity medicine lens to GLP-1 therapy — evaluating which patients are appropriate candidates, selecting and dosing medications carefully, monitoring closely for side effects, and building the lifestyle and nutritional framework that makes medication outcomes durable. Through telehealth care available in North Carolina, California, Florida, and Maine, patients receive the kind of thorough, physician-supervised treatment that produces not just weight loss, but lasting metabolic improvement.

What Are GLP-1 Receptor Agonists?

GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in the gut in response to eating. In the body, GLP-1 plays several important roles: it stimulates insulin secretion in response to blood sugar, suppresses glucagon (which raises blood sugar), slows gastric emptying, and — critically — sends satiety signals to the brain through the central nervous system. GLP-1 receptor agonists are medications that bind to the same receptors as natural GLP-1 but with a much longer duration of action. Naturally produced GLP-1 has a half-life of only a couple of minutes. The injectable medications have half-lives measured in days to a week, allowing for once-weekly dosing that produces sustained hormonal effects.

The most commonly used GLP-1 medications for weight loss include semaglutide (brand names Wegovy for obesity, Ozempic for diabetes) and tirzepatide (Mounjaro for diabetes, Zepbound for obesity). Tirzepatide is technically a dual agonist — it targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, which may contribute to its generally greater weight loss efficacy compared to semaglutide in head-to-head comparisons.

How GLP-1 Injections Produce Weight Loss

Appetite and Satiety Regulation

One of the most clinically significant effects of GLP-1 receptor agonists is their action on hunger and satiety centers in the brain — specifically the hypothalamus and the brainstem. These medications reduce appetite, increase the feeling of fullness after smaller amounts of food, and in many patients, dramatically reduce the preoccupation with food and the urgency of hunger that makes dietary compliance so difficult. Many patients describe the experience of “food noise” — the constant mental preoccupation with eating — disappearing or significantly diminishing. This is not willpower. It is a direct effect of GLP-1 signaling on the central nervous system.

Slowing Gastric Emptying

GLP-1 receptor agonists slow the rate at which food moves from the stomach into the small intestine. This slowing effect contributes to satiety by keeping the stomach fuller for longer after eating. It also reduces post-meal blood sugar spikes by allowing glucose to enter the bloodstream more gradually. For patients with insulin resistance or blood sugar dysregulation, this effect alone can produce meaningful improvements in glucose control and energy balance.

Improving Insulin Sensitivity

Beyond appetite regulation, GLP-1 medications improve insulin secretion in a glucose-dependent manner — meaning they stimulate insulin release only when blood sugar is elevated, which significantly reduces the risk of hypoglycemia compared to older diabetes medications. Over time, the weight loss produced by GLP-1 therapy also directly reduces visceral fat, which in turn further improves insulin sensitivity. Patients on GLP-1 therapy often see improvements in fasting insulin, HbA1c, and inflammatory markers alongside the weight changes.

What Patients Can Realistically Expect

Clinical trials with semaglutide (Wegovy dose) have demonstrated average weight loss of approximately 15 percent of body weight over 68 weeks in patients without diabetes. Tirzepatide trials have shown even higher averages — some cohorts losing 20 percent or more. These are averages, and individual results vary substantially based on medication dose achieved, dietary patterns, activity level, baseline metabolic health, and adherence.

There are several important realistic expectations patients should have:

• Dose escalation takes time: GLP-1 medications are started at low doses and gradually increased over weeks to months to improve tolerability. Most patients reach therapeutic dosing levels over two to five months. The early phase of treatment often produces modest weight loss while the dose escalates.
• Side effects are common early on: Nausea, reduced appetite, constipation, and occasionally mild GI discomfort are the most common early side effects. These typically improve as the body adjusts to the medication, particularly when doses are increased gradually. Physician supervision helps patients manage these effects and avoid discontinuing medication prematurely.
• Lifestyle and nutritional strategies remain important: GLP-1 medications work most effectively when combined with appropriate dietary adjustments and regular physical activity. The medications reduce appetite and improve metabolic function, but patients who use that window to build sustainable habits see better long-term outcomes than those who rely on the medication alone.
• Ongoing monitoring is necessary: Lab work including metabolic panels, HbA1c, fasting insulin, and regular follow-up are important components of well-managed GLP-1 therapy. Physician oversight ensures that medication is producing the intended metabolic benefits and that any concerns are addressed promptly.

Who Is an Appropriate Candidate?

GLP-1 medications are FDA-approved for weight management in patients with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. In clinical practice, obesity medicine-trained physicians also consider the patient’s metabolic profile, history of weight loss vattempts, presence of insulin resistance, and personal goals. These are not medications for modest cosmetic weight loss — they are tools for meaningful medical weight management in patients with clinical need.

Patients who are pregnant, have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, or have certain other medical contraindications are not appropriate candidates. A thorough medical evaluation before starting any GLP-1 therapy is essential.

Conclusion

GLP-1 receptor agonists represent a genuine advance in obesity medicine — not because they are magic, but because they work with the body’s own hormonal systems to address the biological drivers of weight gain in ways that willpower-based approaches cannot. When used appropriately under physician supervision, with proper monitoring and lifestyle support, they can produce meaningful and sustained metabolic improvement for patients who qualify. Understanding how they work, what to expect, and what makes a good candidate helps patients make informed decisions and approach treatment with realistic expectations. Dr. Allison Barbee at SustainMD is here to provide exactly that kind of informed, individualized guidance.

Frequently Asked Questions

1. What is the difference between Ozempic and Wegovy?

Both contain semaglutide, but Ozempic is FDA-approved for type 2 diabetes management, while Wegovy is approved specifically for chronic weight management. Wegovy is available at a higher maximum dose. Which is appropriate depends on your medical situation and insurance coverage.

2. How long does it take to see weight loss results from GLP-1 injections?

Most patients begin to notice reduced appetite within the first few weeks, but meaningful weight loss typically becomes apparent over two to four months as the dose escalates. The greatest weight loss in clinical trials occurs between months three and twelve.

3. Are GLP-1 weight loss injections safe long-term?

Clinical trial data and real-world evidence support the safety of GLP-1 medications for most appropriate candidates over periods of one to two years. Long-term safety data continues to accumulate. Regular physician monitoring is an important component of safe ongoing use.

4. Will I regain weight if I stop taking GLP-1 medication?

Research suggests that many patients experience weight regain after stopping GLP-1 therapy if lifestyle changes have not been established. This is why physician-supervised programs that use the medication window to build durable habits tend to produce better long-term outcomes.

5. Can I use GLP-1 injections if I don’t have diabetes?

Yes. Wegovy (semaglutide) and Zepbound (tirzepatide) are approved specifically for weight management in patients without diabetes who meet BMI criteria. Eligibility is based on weight-related criteria, not a diabetes diagnosis.

6. What is the most effective GLP-1 medication for weight loss?

Clinical trials suggest tirzepatide (Zepbound/Mounjaro) produces greater average weight loss than semaglutide (Wegovy), likely due to its dual GLP-1/GIP mechanism. However, individual response varies, and the best medication depends on your specific health profile and tolerability.

7. Do GLP-1 injections have to be used forever?

Duration of treatment depends on individual circumstances, health goals, and clinical response. Some patients use these medications for a defined period while establishing lifestyle changes; others use them long-term for sustained metabolic management. Talk to your physician about what approach is appropriate for you.

8. What should I eat while taking GLP-1 weight loss medication?

Research and clinical practice suggest prioritizing protein and fiber to preserve lean mass during weight loss, limiting processed and high-glycemic foods to complement the medication’s insulin-sensitizing effects, and eating smaller portions consistent with the appetite reduction the medication produces.

9. Can I get GLP-1 weight loss injections through telehealth?

Yes. SustainMD provides comprehensive medical weight loss evaluation, GLP-1 prescribing, and ongoing monitoring through telehealth appointments for eligible patients in North Carolina, California, Florida, and Maine.

10. Are compounded GLP-1 medications the same as brand-name versions?

Compounded medications contain the same active ingredient but are not FDA-approved products and may vary in quality and concentration. Decisions about compounded versus brand-name GLP-1 medications should be made in consultation with a physician who can evaluate your specific clinical situation and guide you appropriately.